As of 2025-05-25, the Intrinsic Value of Molecular Pharmacology (USA) Ltd (MLPH) is -0.02 USD. This MLPH valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.00 USD, the upside of Molecular Pharmacology (USA) Ltd is -15,200.79%.
Based on its market price of 0.00 USD and our intrinsic valuation, Molecular Pharmacology (USA) Ltd (MLPH) is overvalued by 15,200.79%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.02 - -0.02 | -0.02 | -15,200.79% |
| P/E | (0.00) - (0.00) | (0.00) | -147.1% |
| DDM - Stable | (0.02) - (0.22) | (0.12) | -119678.7% |
| DDM - Multi | 0.00 - 0.00 | 0.00 | -100.0% |
| Market Cap (mil) | 0.01 |
| Beta | -91.65 |
| Outstanding shares (mil) | 111.55 |
| Enterprise Value (mil) | 0.01 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.07% |
| Cost of Debt | 5.00% |
| WACC | 4.87% |